StockData
Tenaya Therapeutics, Inc. logo

Tenaya Therapeutics, Inc. (TNYA) stock

TNYANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$0.32−0.01 (-3.24%)

Close on Nov 17, 2026Market cap $72.38MP/E –Yield –

Tenaya Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Tenaya Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$98.67M. For fiscal 2025 it was -$84.90M. The highest annual figure on record is -$36.43M in fiscal 2020.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$84.90M–
FY2024Dec 31, 2024-$107.48M–
FY2023Dec 31, 2023-$122.51M–
FY2022Dec 31, 2022-$119.15M–
FY2021Dec 31, 2021-$69.85M–
FY2020Dec 31, 2020-$36.43M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$42.39M–
Q1 FY2026Mar 31, 2026-$18.30M–
Q4 FY2025Dec 31, 2025-$18.95M–
Q3 FY2025Sep 30, 2025-$19.04M–
Q2 FY2025Jun 30, 2025-$21.98M–
Q1 FY2025Mar 31, 2025-$24.88M–
Q4 FY2024Dec 31, 2024-$22.56M–
Q3 FY2024Sep 30, 2024-$24.61M–
Q2 FY2024Jun 30, 2024-$28.72M–
Q1 FY2024Mar 31, 2024-$31.61M–
Q4 FY2023Dec 31, 2023-$29.27M–
Q3 FY2023Sep 30, 2023-$28.72M–
Q2 FY2023Jun 30, 2023-$32.90M–
Q1 FY2023Mar 31, 2023-$31.59M–
Q4 FY2022Dec 31, 2022-$32.43M–
Q3 FY2022Sep 30, 2022-$29.20M–
Q2 FY2022Jun 30, 2022-$27.32M–
Q1 FY2022Mar 31, 2022-$30.19M–
Q4 FY2021Dec 31, 2021-$25.37M–
Q3 FY2021Sep 30, 2021-$17.60M–
Q2 FY2021Jun 30, 2021-$14.54M–
Q1 FY2021Mar 31, 2021-$12.42M–
Q4 FY2020Dec 31, 2020-$9.66M–
Q3 FY2020Sep 30, 2020-$9.85M–
Q2 FY2020Jun 30, 2020-$8.27M–

More Tenaya Therapeutics figures

See a number that looks wrong?